Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies

By Deenen Maarten  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1557-1565

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies

By Chen Eric   Batist Gerald   Siu Lillian   Bangash Naeema   Maclean Martha   McIntosh Lynn   Miller Wilson   Oza Amit   Lathia Chetan   Petrenciuc Oana   Seymour Lesley  

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 455-465

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies

By Cho Cheryl   Fisher George   Halsey Joanne   Sikic Branimir  

Investigational New Drugs, Vol. 24, Iss. 2, 2006-03 ,pp. : 117-123

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies

By Sayar H.   Shen Z.   Lee S.   Royce M.   Rabinowitz I.   Lee F.   Smith H.   Eberhardt S.   Maestas A.   Lu H.   Verschraegen C.  

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 153-158

Springer Publishing Company

Access to resources Recommend Favorite

Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study

By Blais Normand   Camidge D.   Jonker Derek   Soulières Denis   Laurie Scott   Diab Sami   Ruiz-Garcia Ana   Thall Aron   Zhang Ke   Chao Richard   Chow Laura  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1487-1498

Springer Publishing Company

Access to resources Recommend Favorite